In the third quarter, we may have results available in the first and second dosing levels completed. The third dosing levels may not yet be completed by then, but again it may.
Are not unique to ICPT but to every drug developers with a novel treatment for an unmet medical need. If insurers target and single out OCA, there will be a public repercussion.
Only went down to 217 after controversies on press releases and e- mail between NIDDK and ICPT were revealed. Now that hose issues were put to rest as well as confirmation of better positive results of OCA on Flint trial, it is unlikely the PT will go lower than before as predicted by FBR. Remember ther are 10 analysts with higher PT compared to one by FBR. All ten cannot be wrong!
Actually there are more than 5 analysts with positive views on ICPT. They are citi, needham,BMO,RBC,Oppenheimer,Wedbush,Nomura,Leerink,Deutsche Bank and Summer Street
Do you believe that ICPT and the other companies developing drug for NASH disease have not explored this scenario even before starting with their first trial on lab animals?
For example, hepatologist will not get paid for treating both HCV and NASH. They are different diseases, HCV is infectious disease, the other metabolic syndrome although both affect the liver. How come nephrologists are being paid for kidney dialysis and treating chrnic kidney infection? There is no treatment paradigms, of course NASH has no effective drug available in the market yet. OCA will be the first. Because of significant co-morbidities of NASH, lipid studies have to be done first before approval.ICPT is already going to do that.Don't tell me these prople are getting paid for printing nonsense.
I see better days ahead at ICPT. PBC and NASH are inside their pocket now. Even CEO Mark P was surprised at the strength of OCA on liver disease. He even commented at the CC that " we underestimate the strength of OCA." Next trial will be on PSC and that also will be successful. He described it as the brother of PBC since it is more common in male while PBC is a disease of women. Big thing is no more issue on safety. Dosing adjustment may even be considered on NASH, that is, lower stage disease gets lower dose while higher stage disease will get higher dose thus balancing risk vs benefit. Cannot tell you what to do but I am not selling .
Deferred till first quarter of 2015. FLINT data only got delayed for 11 days and the stock tanked.